A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs.
Mol Cell Oncol
; 8(2): 1871172, 2021 Jan 30.
Article
en En
| MEDLINE
| ID: mdl-33855167
ABSTRACT
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated cells persist through maintenance of the mitogen-activated protein kinase Interacting Serine/Threonine Kinase 1 (MKNK1) - Extracellular Signal-regulated Kinase (ERK)-axis by hijacking the splicing machinery through post-translational modifications.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Mol Cell Oncol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Alemania